MedPath

广东鼎信医药科技有限公司

Ownership
-
Established
2018-09-14
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

34

NMPA:34

Drug Approvals

Rifampicin for Injection

Product Name
注射用利福平
Approval Number
国药准字H20249368
Approval Date
Nov 15, 2024
NMPA

Cerebroprotein Hydrolysate Injection

Product Name
脑蛋白水解物注射液
Approval Number
国药准字H22025355
Approval Date
Feb 20, 2024
NMPA

Cerebroprotein Hydrolysate Injection

Product Name
脑蛋白水解物注射液
Approval Number
国药准字H22024609
Approval Date
Feb 2, 2024
NMPA

Cerebroprotein Hydrolysate Injection

Product Name
脑蛋白水解物注射液
Approval Number
国药准字H22025356
Approval Date
Feb 2, 2024
NMPA

Chorionic Gonadotrophin for Injection

Product Name
注射用绒促性素
Approval Number
国药准字H22026348
Approval Date
Nov 27, 2023
NMPA

鹿茸精注射液

Approval Number
国药准字Z22024358
Approval Date
Aug 29, 2023
NMPA

Piracetam Injection

Product Name
吡拉西坦注射液
Approval Number
国药准字H22024146
Approval Date
Aug 4, 2023
NMPA

Piracetam Injection

Product Name
吡拉西坦注射液
Approval Number
国药准字H20227156
Approval Date
Aug 4, 2023
NMPA

Piracetam Injection

Product Name
吡拉西坦注射液
Approval Number
国药准字H22024151
Approval Date
Aug 4, 2023
NMPA

Pefloxacin Mesylate for Injection

Product Name
注射用甲磺酸培氟沙星
Approval Number
国药准字H20057928
Approval Date
Jan 12, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.